Direct-acting antiviral treatment in adults infected with hepatitis C virus: Reactivation of hepatitis B virus coinfection as a further challenge
Use of direct-acting antiviral drugs (DAAs) greatly improves management of adults infected with hepatitis C virus (HCV) whether patients are treatment-naive or unsuccessfully pre-treated. Several inhibitors of viral nonstructural proteins (NS3/4A protease, NS5A and NS5B polymerase) allow a rapid HCV clearance and increase rates of sustained virological response. Both the EASL and AASLD guidelines have recently published up-to-date recommendations for their use, addressing each HCV genotype and particular situations. However, management of patients coinfected with hepatitis B virus (HBV) has been developed by these guidelines with reference to cases of HBV reactivation reported during previous anti-HCV regimens containing interferon known active against both HBV and HCV. In the setting of the interferon-free HCV therapies with DAAs only, the possibility of HBV reactivation during treatment of hepatitis C is raised due to viral interferences in HCV/HBV coinfected persons. Herein, we report a case of early HBV reactivation during DAAs-based anti-HCV treatment (ledipasvir/sofosbuvir) in a patient having a resolved HBV infection and chronically infected with HCV genotype 4 and HIV. Moreover, we review similar recent cases of HBV reactivation in patients infected with HBV and HCV genotype 1 during treatment of hepatitis C by regimen incorporating other combination of DAAs (sofosbuvir/simeprevir or daclatasvir/asunaprevir). Due to the potential risk of early HBV reactivation in HCV/HBV-coinfected patients during interferon-free DAAs-based HCV therapies, altogether these cases highlight the necessity to closely monitor HBV coinfection, regardless its stage (chronic, occult, resolved), whatever HCV genotype or class of DAAs used..
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2016 |
|---|---|
| Erschienen: |
2016 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:78 |
|---|---|
| Enthalten in: |
Journal of clinical virology - 78(2016), Seite 27-30 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
De Monte, Anne [VerfasserIn] |
|---|
| Links: |
|---|
| doi: |
10.1016/j.jcv.2016.02.026 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
OLC1975964829 |
|---|
| LEADER | 01000caa a2200265 4500 | ||
|---|---|---|---|
| 001 | OLC1975964829 | ||
| 003 | DE-627 | ||
| 005 | 20230508082151.0 | ||
| 007 | tu | ||
| 008 | 160609s2016 xx ||||| 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jcv.2016.02.026 |2 doi | |
| 028 | 5 | 2 | |a PQ20160719 |
| 035 | |a (DE-627)OLC1975964829 | ||
| 035 | |a (DE-599)GBVOLC1975964829 | ||
| 035 | |a (PRQ)c1784-1d1efb83bb67fd7cf5a9cef592582227e000d5f8b3d3a140f397c2f338557f630 | ||
| 035 | |a (KEY)0226722520160000078000000027directactingantiviraltreatmentinadultsinfectedwith | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q DNB |
| 100 | 1 | |a De Monte, Anne |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Direct-acting antiviral treatment in adults infected with hepatitis C virus: Reactivation of hepatitis B virus coinfection as a further challenge |
| 264 | 1 | |c 2016 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 520 | |a Use of direct-acting antiviral drugs (DAAs) greatly improves management of adults infected with hepatitis C virus (HCV) whether patients are treatment-naive or unsuccessfully pre-treated. Several inhibitors of viral nonstructural proteins (NS3/4A protease, NS5A and NS5B polymerase) allow a rapid HCV clearance and increase rates of sustained virological response. Both the EASL and AASLD guidelines have recently published up-to-date recommendations for their use, addressing each HCV genotype and particular situations. However, management of patients coinfected with hepatitis B virus (HBV) has been developed by these guidelines with reference to cases of HBV reactivation reported during previous anti-HCV regimens containing interferon known active against both HBV and HCV. In the setting of the interferon-free HCV therapies with DAAs only, the possibility of HBV reactivation during treatment of hepatitis C is raised due to viral interferences in HCV/HBV coinfected persons. Herein, we report a case of early HBV reactivation during DAAs-based anti-HCV treatment (ledipasvir/sofosbuvir) in a patient having a resolved HBV infection and chronically infected with HCV genotype 4 and HIV. Moreover, we review similar recent cases of HBV reactivation in patients infected with HBV and HCV genotype 1 during treatment of hepatitis C by regimen incorporating other combination of DAAs (sofosbuvir/simeprevir or daclatasvir/asunaprevir). Due to the potential risk of early HBV reactivation in HCV/HBV-coinfected patients during interferon-free DAAs-based HCV therapies, altogether these cases highlight the necessity to closely monitor HBV coinfection, regardless its stage (chronic, occult, resolved), whatever HCV genotype or class of DAAs used. | ||
| 540 | |a Nutzungsrecht: © Elsevier B.V. | ||
| 540 | |a Copyright © 2016 Elsevier B.V. All rights reserved. | ||
| 700 | 1 | |a Courjon, Johan |4 oth | |
| 700 | 1 | |a Anty, Rodolphe |4 oth | |
| 700 | 1 | |a Cua, Eric |4 oth | |
| 700 | 1 | |a Naqvi, Alissa |4 oth | |
| 700 | 1 | |a Mondain, Véronique |4 oth | |
| 700 | 1 | |a Cottalorda, Jacqueline |4 oth | |
| 700 | 1 | |a Ollier, Laurence |4 oth | |
| 700 | 1 | |a Giordanengo, Valérie |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of clinical virology |d Amsterdam [u.a.] : Elsevier, 1998 |g 78(2016), Seite 27-30 |w (DE-627)24946909X |w (DE-600)1446080-4 |w (DE-576)070381798 |x 1386-6532 |7 nnns |
| 773 | 1 | 8 | |g volume:78 |g year:2016 |g pages:27-30 |
| 856 | 4 | 1 | |u http://dx.doi.org/10.1016/j.jcv.2016.02.026 |3 Volltext |
| 856 | 4 | 2 | |u http://www.sciencedirect.com/science/article/pii/S1386653216300178 |
| 856 | 4 | 2 | |u http://www.ncbi.nlm.nih.gov/pubmed/26967675 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_OLC | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a SSG-OLC-DE-84 | ||
| 912 | |a GBV_ILN_4219 | ||
| 951 | |a AR | ||
| 952 | |d 78 |j 2016 |h 27-30 | ||